Mr. Bleil has more than 15 years of experience providing financial advisory services in mergers and acquisitions, corporate finance and valuation.
Mr. Bleil's transaction experience encompasses a broad range of industries, with a particular focus in the healthcare, industrial services, manufacturing and consumer sectors.
During his career, Mr. Bleil has advised clients on transactions totaling more than $10 billion in aggregate value.
His past engagements have included the Primedex Health Systems (OTCBB: PMDX) acquisition of Radiologix (AMEX: RGX); the Harsco Corporation (NYSE: HSC) acquisitions of Hunnebeck Group GmbH, Excell Materials and Bell Scaffolding Group; the Saint-Gobain (ENXTPA: SGO) divestiture of its North American security glass business; the ADP (NYSE: ADP) divestiture of ADP Graphic Communications; the Claymont Steel Holdings (NASDAQ: PLTE) sale to Evraz Group (LSE: EVR); and the NexCen Brands (NASDAQ: NEXC) acquisitions of The Athlete's Foot, Bill Blass Holdings and MaggieMoo's / Marble Slab.
He also has extensive experience providing fairness opinions in connection with change of control and related party transactions. He has provided opinions to clients on transactions totaling more than $5 billion in aggregate value.
Prior to joining A&M, Mr. Bleil was Head of Mergers & Acquisitions and Corporate Finance in the Healthcare Banking group at RBS Citizens. He was also Director, Mergers & Acquisitions at Bank of America Merrill Lynch and Senior Vice President, Mergers & Acquisitions at Jefferies & Company. Mr. Bleil began his Wall Street career in the Mergers & Acquisitions Group at Donaldson, Lufkin & Jenrette.
He earned a bachelor's degree in economics from the University of Pennsylvania and a master's degree in business administration from New York University. He is a licensed General Securities Registered Representative (Series 79).